![Page 1: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/1.jpg)
Antibody mediated in vivo
delivery of
small interfering RNAs
via cell-surface receptorsFrom “nature biotechnology”
Presented by
V.Esakki Muthu Lakshmi
![Page 2: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/2.jpg)
Introduction
Protamine-antibody fusion(F105-P)
Fab fragment
siRNA delivery
Gene silencing in target cells
HIV env expressing cells
Cancer cells
![Page 3: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/3.jpg)
siRNA function
19-25 nucleotides long
Antiviral defense mechanism
Transposon silencing
Gene regulation
Chromosomal modification
![Page 4: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/4.jpg)
siRNA mechanism
![Page 5: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/5.jpg)
Antibody structure
2 heavy chains
2 light chains
Disulfide bonds
Glycoproteins
Antigen specificity
Bivalent binding sites
![Page 6: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/6.jpg)
Need for protamine-antibody fusion
Protamine
Cationic peptide
Binds to C terminus of Ab
Links Ab and siRNA
To avoid
Nonspecific gene silencing
Toxicity in bystander cells
![Page 7: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/7.jpg)
![Page 8: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/8.jpg)
Targeting of HIV env+ cells
COS cells
Fibroblast like cell line
Medium-RPMI1640 with 10% fetal bovine serum
Transfection with pCMV-F105-P
Collection of F105-P*
B16 cells
Melanoma cells
Transfection with expression vector for HIV env
FITC*-siRNA
FITC*-Flourescin isothio cyanate
F105-P* – protamine antibody against HIV env
![Page 9: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/9.jpg)
F105-P binding assay
Addition of 200 pmol FITC-siRNA
Anti-protamine coated protein bound F105-P
overnight incubation at 4°C
Thorough washing to remove unbound FITC-siRNA
Determination of absorbance at 488nm
Construction of standard curve
![Page 10: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/10.jpg)
1 F105-P binds to ~6 siRNA
molecules
RESULTS
![Page 11: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/11.jpg)
siRNA delivery Mixing of F105-P & gag siRNA (6:1)
Incubation of mixture in PBS at 4°C
Addition of mixture to cells(B16)
Transfection of cells with oligofectamine*(control)
Analysis of gene expression 2days after of siRNA
delivery
gag siRNA-gene silencing in HIV env expressing cells
Oligofectamine*-tranfection reagent
![Page 12: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/12.jpg)
RESULT(northern blot
analysis)
![Page 13: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/13.jpg)
Analysis of target gene silencing
Transfection of HeLa* cells with plasmid encoding
EGFP
Tranfection of HeLa-GFP with HIV λHXB3
Treating of culture with F105-p EGFP siRNA
Analysis of HIV & GFP expression 2d after treatment
GFP expression by northern blot
HeLa*-immortal cell line
EGFP-enhanced green flourescent protein
![Page 14: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/14.jpg)
RESULTAbsence of gene silencing
untransfected gag p24(-) cells
Irrelevant fas siRNA
Unmodified F105 in place of F105-P
Loading
control
![Page 15: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/15.jpg)
Inhibition of HIV in infected T cells
Collection of CD4 T cells from normal donor
Stimulation with phytohemagglutinin*(4µg/ml) for 4d
Infection with HIV strain III B at a MOI of 0.1
Treating cells with F105-P -gag siRNA
Analysis of HIV replication
Phytohemagglutinin*-mitogen
![Page 16: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/16.jpg)
RESULTS
Reduction in infected cells(85%-36%)
HIV gag staining-45%
ELIZA for HIV p24
Concentration of viral particle -170 ng/ml to
40 ng/ml(100 pmol of siRNA)
![Page 17: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/17.jpg)
HIV gag staining
![Page 18: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/18.jpg)
ELISA for p24 Ag
![Page 19: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/19.jpg)
Tumor cell proliferation inhibition
BL6/C57 mice
Subcutaneous injection of gp160-B16 cells(5× 106 )
Intravenous injection of F105-P
1. c-myc siRNA
2. MDM2 siRNA
3. VEGF siRNA
F105-P:siRNA-1:6
Sectioning of tumor
from killed mice(9d)
Analysis of expression by
q RT-PCR or flow cytometry
![Page 20: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/20.jpg)
RESULTS
F105-P-cmyc siRNA
Effect on gp160-B16 cells(si RNA conc>100nM)
No effect on B16-gp160(-) cells
F105-P-VEGF siRNA
Modest effect
Blocking of angiogenesis
F105-P -GFP siRNA(control)
Target tumor suppressor pp32
![Page 21: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/21.jpg)
Contd…
F105-p-VEGF,MDM2&c-myc siRNA
The greatest effect on gp160-B16 cells
![Page 22: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/22.jpg)
![Page 23: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/23.jpg)
![Page 24: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/24.jpg)
Determination of specificity
BL6/C57 mice
Subcutaneous injection of gp160-B16 cells(2× 106 )
Intravenous injection of 50µg F105-P-FITC
siRNA(day 9)
Transfection with oligofectamine
Cryosectioning of tumor from killed mice(16h)
OBSERVATION
Effect on gp160+ tumor cells
Flourescent signal in membrane & cytoplasm,not
in tumor cell nucleus
![Page 25: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/25.jpg)
![Page 26: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/26.jpg)
Is there any inflammatory responses?
Possibilities
Trigger an interferon responses
Binding of siRNA to TLR*
q RT-PCR
Interferon beta
2’,5’-oligoadenylate synthetase
Stat-1
Observation
No interferon responses
TLR*-Toll like receptor
![Page 27: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/27.jpg)
RESULT
![Page 28: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/28.jpg)
Single chain fragment variable
2 variable domains-VH&VL
High antigen specificity
![Page 29: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/29.jpg)
Anti ErB2 ML39 scFV production
Transfection of SF9 cells with virus(ML39 scFV)
Extraction of ML39 scFV by 6M GuanHCl
Purification by Ni++ chromatography
Dialysis with PBS containing 5%glycerol,0.5M
arginine,1mM EGTA,1mM glutathione
Final dialysis with PBS containing 5%glycerol
![Page 30: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/30.jpg)
![Page 31: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/31.jpg)
![Page 32: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/32.jpg)
FITC siRNA delivery by ML39 scFV-P
Targeting cells
ErB2 expressing cells
MCF7 breast cancer cells
SKBR3 cells
Observation
effect only in ErB2+ cells
Ku70 silencing in ErB2+ SKBR3 cells
Dose of ML39 scFV-P – 1000pmol
![Page 33: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/33.jpg)
![Page 34: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/34.jpg)
Conclusion
Rate limiting factor
Short in vivo half-life
Filtering of siRNA
Prone to Rnase activity
Gene silencing enhancement
Modified siRNA
Cocktails of siRNA
Chemokine analog
![Page 35: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/35.jpg)
![Page 36: Antibody mediated in vivo delivery of siRNA via cell surface receptors](https://reader036.vdocuments.us/reader036/viewer/2022081404/55a1dc551a28abdb198b47f7/html5/thumbnails/36.jpg)